breast cancer progression
Showing 1 - 25 of >10,000
Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic Trial in Boston (Sacituzumab Govitecan,
Not yet recruiting
- Her 2 Positive Breast Cancer
- +2 more
- Sacituzumab Govitecan
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 25, 2023
HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))
Not yet recruiting
- HER2-positive Breast Cancer
- Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
- (no location specified)
Jul 20, 2023
Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))
Recruiting
- Advanced Breast Cancer
- +2 more
- Trastuzumab Emtansine (T-DM1)
-
Nanjing, Jiangsu, ChinaJiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Nov 5, 2023
CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent
Not yet recruiting
- Breast Cancer
- +3 more
- Different treatment regimens following progression on CDK4/6 inhibitors.
- (no location specified)
Sep 5, 2023
Breast Cancer Stage IV Trial in Mansoura (comparing both arms as regard the objective response rate, toxicity profile, quality
Recruiting
- Breast Cancer Stage IV
- comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
-
Mansoura, Dakahlia, EgyptOncology center mansoura university
Jan 1, 2023
A NIS of Alpelisib in Combination With Fulvestrant in
Not yet recruiting
- Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
- Alpelisib
- Fulvestrant
- (no location specified)
Aug 9, 2022
Metastatic Breast Cancer Trial in Springfield, Rochester, Lebanon (17B-estradiol, Letrozole, Anastrozole)
Active, not recruiting
- Metastatic Breast Cancer
- 17B-estradiol
- +3 more
-
Springfield, Massachusetts
- +2 more
Nov 1, 2022
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer Trial in
Recruiting
- Hormone Receptor Positive Breast Carcinoma
- +2 more
- Alpelisib
- +2 more
-
Chicago, Illinois
- +2 more
Jul 1, 2022
Breast Cancer, Breast Cancer Treatment Related Lymphedema Trial in Boston (Juzo Compression Sleeve and Glove, Compression Sleeve
Not yet recruiting
- Breast Cancer
- Breast Cancer Treatment Related Lymphedema
- Juzo Compression Sleeve and Glove
- Compression Sleeve Sensor
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
Jan 12, 2023
Breast Cancer Invasive, Metastatic Cancer, Oligoprogressive Trial in Amsterdam (procedure, radiation, other)
Not yet recruiting
- Breast Cancer Invasive
- +2 more
- Surgery
- +2 more
-
Amsterdam, NetherlandsAntoni van Leeuwenhoek
Mar 21, 2022
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer Trial in
Terminated
- Estrogen Receptor-positive Breast Cancer
- +7 more
- everolimus
- +5 more
-
Atlanta, Georgia
- +2 more
Mar 10, 2022
Tumor, Breast, Congenital, Familial and Genetic Disorders Trial in Netherlands (Alpelisib 150 MG Oral Tablet [Piqray],
Recruiting
- Neoplasm, Breast
- Congenital, Familial and Genetic Disorders
- Alpelisib 150 MG Oral Tablet [Piqray]
- Fulvestrant
-
Almelo, Netherlands
- +15 more
Jan 11, 2023
ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer Trial in Madison, Milwaukee (Onapristone, Fulvestrant)
Recruiting
- ER-positive Breast Cancer
- +2 more
-
Madison, Wisconsin
- +1 more
Jul 7, 2022
Solid Tumor, Adult Trial (EOC202, albumin-bound paclitaxel)
Not yet recruiting
- Solid Tumor, Adult
- EOC202
- albumin-bound paclitaxel
- (no location specified)
Apr 7, 2022
Advanced Breast Cancer Trial in China (Everolimus, Exemestane, Everolimus Placebo)
Completed
- Advanced Breast Cancer
- Everolimus
- +2 more
-
Guangzhou, Guangdong, China
- +14 more
Jun 17, 2022
Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)
Active, not recruiting
- Metastatic Breast Cancer
-
Hospitalet de Llobregat, Barcelona, Spain
- +6 more
Jan 23, 2023
FES F18 PET/CT in Metastatic Breast Cancer Patients
Recruiting
- Metastatic Breast Cancer
- 18F Fluoroestradiol Radiopharmaceutical with PET/CT
-
Long Beach, California
- +5 more
Jan 19, 2023
Advanced Solid Tumor, Breast Cancer Trial in Columbus, San Antonio, West Valley City (CFI-402257, Fulvestrant)
Recruiting
- Advanced Solid Tumor
- Breast Cancer
-
Columbus, Ohio
- +2 more
Jul 26, 2022
Metastatic Breast Cancer With a Isolated Brain Progression Trial in France (Tucatinib, Pertuzumab, Trastuzumab)
Recruiting
- Metastatic Breast Cancer With a Isolated Brain Progression
- Tucatinib
- +4 more
-
Angers, France
- +33 more
Aug 10, 2022
Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer Trial in United States (Stereotactic body
Recruiting
- Oligometastatic Breast Carcinoma
- +5 more
- Stereotactic body radiotherapy
-
Basking Ridge, New Jersey
- +6 more
Sep 6, 2022
Breast Cancer, Breast Tumors, Breast Cancer Female Trial (Soy isoflavones, Lignans, Placebo)
Withdrawn
- Breast Cancer
- +2 more
- Soy isoflavones
- +2 more
- (no location specified)
May 10, 2021
Breast Cancer Trial in Singapore (Lenvatinib + Letrozole, Fulvestrant)
Not yet recruiting
- Breast Cancer
- Lenvatinib + Letrozole
- Fulvestrant
-
Singapore, SingaporeNationa University Hospital
Jan 4, 2022
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2
Recruiting
- Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
-
Duarte, California
- +12 more
Jul 6, 2022